Maternal obesity is a modifiable risk factor.
Initiating statin therapy was independently linked to a modestly higher incident diabetes rate.
Continue to focus on a healthy dietary pattern.
Drugmaker’s marketing application is under EMA review.
Study finds strong associations of serum non-HDL-C and CVD risk.
It’s not too late for people with MetS to get treatment and reduce risks.
Benefit of 6 months of aerobic exercise was still evident a year after the intervention ended.
1 exception is more rapid logical memory decline in men taking statins.
DAPA offers a new approach to treating HFrEF in patients regardless of T2D.
Statin-related memory and/or cognitive changes are reported frequently.
Treat Stroke to Target trial results favor intensive LDL lowering to less than 70 mg/dL.
Adequate risk factor control could avert up to half of all ischemic strokes.
Short 12-week trial suggests room for therapeutic improvement in these patients.
CV risk factor control was better, but smoking cessation and retinopathy screening lag.
Cochrane review update leaves long-term safety an unknown.
Higher serum elaidic acid levels conferred elevated risks for all-cause dementia, AD.
If 2-year mortality risk is low, statins may offer benefit.
